Yilmaz V, Tuzun E, Durmus-Tekce H, et al. - Researchers analyzed generalized non-thymomatous myasthenia gravis (MG) patients, to investigate B cell related factors concerning immunosuppressive treatment in this patient population. Among disease subgroups, no difference was evident in CD19+ B cell distribution, but there were changes in the expressions of both CD38 and BAFFR on B cells in MG patients under immunosuppressive treatment. Raised serum levels of BAFF were detected in untreated MG patients vs treated MG patients and healthy controls. Profound alterations because of immunosuppression may be demonstrated by B cell activation factors.